BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27225851)

  • 21. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
    Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
    Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body.
    Oikawa M; Sakamoto N; Kobayashi A; Suzuki S; Yoshihisa A; Yamaki T; Nakazato K; Suzuki H; Saitoh S; Kiko Y; Nakano H; Hayashi T; Kimura A; Takeishi Y
    BMC Cardiovasc Disord; 2016 May; 16():83. PubMed ID: 27160240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Diagnosis of Fabry disease: usefulness of the clinical investigation].
    Demontis R
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S229-32. PubMed ID: 21211670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of Fabry disease in patients with hypertrophic cardiomyopathy: How to guide the diagnostic strategy?
    Azevedo O; Marques N; Reis L; Cruz I; Craveiro N; Antunes H; Lourenço C; Gomes R; Guerreiro RA; Faria R; Sá F; Lima R; Gaspar P; Faria R; Miltenberger-Miltenyi G; Sousa N; Cunha D;
    Am Heart J; 2020 Aug; 226():114-126. PubMed ID: 32531501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population.
    Lin HY; Chong KW; Hsu JH; Yu HC; Shih CC; Huang CH; Lin SJ; Chen CH; Chiang CC; Ho HJ; Lee PC; Kao CH; Cheng KH; Hsueh C; Niu DM
    Circ Cardiovasc Genet; 2009 Oct; 2(5):450-6. PubMed ID: 20031620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost Efficacy of α-Galactosidase A Enzyme Screening for Fabry Disease.
    Newman DB; Miranda WR; Matern D; Peck DS; Geske JB; Maleszewski JJ; Ommen SR; Ackerman MJ
    Mayo Clin Proc; 2019 Jan; 94(1):84-88. PubMed ID: 30611458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of Electrocardiography to Distinguish Fabry Disease from Sarcomeric Hypertrophic Cardiomyopathy.
    Antezana-Chavez E; Cianciulli TF; Hadid CL; Toro DD; Celano L; Saccheri MC; Baez KG; Lopez CA; Labadet CD; Gagliardi JA
    Am J Cardiol; 2022 Sep; 178():131-136. PubMed ID: 35810008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fabry disease presenting as apical left ventricular hypertrophy in a patient carrying the missense mutation R118C.
    Caetano F; Botelho A; Mota P; Silva J; Leitão Marques A
    Rev Port Cardiol; 2014 Mar; 33(3):183.e1-5. PubMed ID: 24661928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
    De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
    Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey.
    Elliott P; Baker R; Pasquale F; Quarta G; Ebrahim H; Mehta AB; Hughes DA;
    Heart; 2011 Dec; 97(23):1957-60. PubMed ID: 21890869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic dilemmas in Fabry disease: a case series study on GLA mutations of unknown clinical significance.
    Smid BE; Hollak CE; Poorthuis BJ; van den Bergh Weerman MA; Florquin S; Kok WE; Lekanne Deprez RH; Timmermans J; Linthorst GE
    Clin Genet; 2015 Aug; 88(2):161-6. PubMed ID: 25040344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy.
    Sadasivan C; Chow JTY; Sheng B; Chan DKH; Fan Y; Choi PCL; Wong JKT; Tong MMB; Chan TN; Fung E; Kam KKH; Chan JYS; Chi WK; Paterson DI; Senaratne M; Brass N; Oudit GY; Lee APW
    PLoS One; 2020; 15(9):e0239675. PubMed ID: 32987398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of subclinical fabry disease in patients presenting with hypertrophic cardiomyopathy.
    Ackerman MJ; Landstrom AP
    J Am Coll Cardiol; 2007 Dec; 50(25):2404-5. PubMed ID: 18154966
    [No Abstract]   [Full Text] [Related]  

  • 34. Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results.
    Linthorst GE; Poorthuis BJ; Hollak CE
    J Am Coll Cardiol; 2008 May; 51(21):2082; author reply 2082-3. PubMed ID: 18498967
    [No Abstract]   [Full Text] [Related]  

  • 35. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance.
    Smid BE; van der Tol L; Cecchi F; Elliott PM; Hughes DA; Linthorst GE; Timmermans J; Weidemann F; West ML; Biegstraaten M; Lekanne Deprez RH; Florquin S; Postema PG; Tomberli B; van der Wal AC; van den Bergh Weerman MA; Hollak CE
    Int J Cardiol; 2014 Dec; 177(2):400-8. PubMed ID: 25442977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
    Beer G; Reinecke P; Gabbert HE; Hort W; Kuhn H
    Z Kardiol; 2002 Dec; 91(12):992-1002. PubMed ID: 12490989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of the alpha-galactosidase A gene single nucleotide polymorphism -10C>T: A single-center observational study.
    Oder D; Liu D; Üçeyler N; Sommer C; Hu K; Salinger T; Müntze J; Petritsch B; Ertl G; Wanner C; Nordbeck P; Weidemann F
    Medicine (Baltimore); 2018 May; 97(21):e10669. PubMed ID: 29794742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype.
    Azevedo O; Gal A; Faria R; Gaspar P; Miltenberger-Miltenyi G; Gago MF; Dias F; Martins A; Rodrigues J; Reimão P; Pereira O; Simões S; Lopes E; Guimarães MJ; Sousa N; Cunha D
    Mol Genet Metab; 2020 Feb; 129(2):150-160. PubMed ID: 31519519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genotype-Phenotype Correlations in 293 Russian Patients with Causal Fabry Disease Variants.
    Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Pakhomov A; Trufanova E; Alexeeva A; Sladkov D; Kuzenkova L; Asanov A; Fisenko A
    Genes (Basel); 2023 Oct; 14(11):. PubMed ID: 38002959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of Fabry's disease within hemodialysis patients in Spain.
    Herrera J; Miranda CS
    Clin Nephrol; 2014 Feb; 81(2):112-20. PubMed ID: 24365053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.